Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing first-in-class immunology, immuno-oncology and anti-addiction therapeutics. Omeros’ pipeline is led by its complement franchise targeting MASP-2, the effector enzyme of the lectin pathway of complement, and MASP-3, the key activator of the alternative pathway. The MASP-2 inhibitor narsoplimab has been granted FDA’s Breakthrough Therapy and Orphan designations and EMA’s Orphan designation for IgA nephropathy and is currently in Phase 3 development for this indication.